# A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC

Source: https://onco.cc/trials/nct04316364/  
OnCo record `nct04316364` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC is a phase 3 interventional study registered as NCT04316364 by Jiangsu HengRui Medicine Co., Ltd., with 537 participants planned, started 2020-07-14 and due to reach its primary completion in 2023-04-15. Interventions recorded: SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin, SHR-1316、Chemotherapeutic, Placebo、Chemotherapeutic. Conditions listed: Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04316364
- Phase: 3
- Setting: A Randomized, Double-Blind, Multicenter, Phase Ib/III Clinical Study on PD-L1 Monoclonal Antibody SHR-1316 or Placebo in Combination With Chemotherapy as Perioperative Treatment of Resectable Stage II or III Non-Small Cell Lung Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 537

## Sources

- ClinicalTrials.gov NCT04316364: https://clinicaltrials.gov/study/NCT04316364

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct04316364.json